Conference Day One Agenda - March 26 2025
7:30 am Check In & Registration
8:20 am Chair’s Opening Remarks
Optimizing Bispecific ADCs for Increased Tumor Specificity & Widened Therapeutic Index
8:30 am Leveraging Bi-Cygni Bispecific Antibody Drug Conjugates for High Selectivity Against Solid Tumors
Synopsis
- An introduction to BiVictriX’s proprietary bispecific ADC approach in a solid tumor setting
- Reviewing shared from the lead solid tumor bispecific ADC program
- Observing tumor growth inhibition and tumor regressions observed at well-tolerated doses in a murine model of ovarian cancer
9:00 am Targeted 225Ac Therapy for Cancer Using Small Molecule-, Peptide- & Antibody-Based Vectors
Synopsis
- Considering if targeted radiotherapy is any better than targeted chemotherapy?
- Considering why 225Ac is an attractive payload for cancer therapy
- Discussing Ligand … diversity: What’s optimal for solid tumor therapy?
9:30 am Expanding the Scope of Established Platform Technologies to Adapt to Next Generation Conjugates
Synopsis
- Assessing how novel conjugates necessitate novel solutions to develop scalable processes and reliable analytical methods in order to bring these therapeutics to the clinic, but reinventing the wheel each time is impractical
- Leveraging a combination of literature research and development experience, we have augmented our traditional ADC platforms to accommodate efficient development and manufacturing of next generation conjugates
- This talk will cover some of these challenges and platform retrofitting solutions
10:00 am Morning Break & Speed Networking
Synopsis
The ideal opportunity to network with many of the brightest minds in bioconjugate development, get to know the current state-of-play in the field and form new connections for important in-depth conversations
11:00 am Spotlighting Synergy: Embracing High-Throughput Discovery & Development of Monospecific & Bispecific Drug Conjugates
Synopsis
- Outlining a approach to conjugate design, where equal emphasis is placed on optimizing each component – from payload to linker to targeting binders
- Discussing the transformative potential of bispecific drug-conjugates, including bispecific ADCs (bsADCs)
- Showcasing innovative methodology enabling rapid iteration and high-throughput screening of conjugates, allowing for the creation of thousands of candidates in mere weeks
11:30 am Biparatopic ADCs: Enhancing Binding & Internalization for Improved Cytotoxic Efficacy
Synopsis
- Leveraging biparatopic ADCs to enhance drug binding and internalization, leading to improved ADC cytotoxic efficacy
- Understanding the preclinical safety and efficacy data from Salubris Bio’s lead biparatopic ADC molecule
- Reviewing translation into the clinic and early clinical experience so far
12:00 pm Networking Lunch
DACs: Combining the Power of Protein Degraders With the Precision of Antibodies for Synergistic Potential
1:30 pm PROTAb Platform: An Innovative Universal Linker for DACs With CereblonBased Degraders
Synopsis
- An introduction into PROTAb – Orum’s traceless linker technology for Degrader-Antibody Conjugate (DAC). It improves the effectiveness of cereblon-based degraders by enabling stable conjugation to therapeutic antibodies
- Understanding the technology used, including a Mannich base self-immolative spacer to form stable DAC, releasing the active degrader tracelessly upon intracellular triggering
- Reviewing the versatility and compatibility with various conjugation methods, and the enhancement of drug-like characteristics. This approach ensures effective targeted protein degradation in diverse cellular contexts
2:00 pm Design & Preclinical Evaluation of Degrader Antibody Conjugates
Synopsis
- Optimization of linker payload
- A demonstration of targeted protein degradation in vitro
- Preclinical efficacy observed with antibodies targeting multiple tumor associated antigens in xenograft models
2:30 pm Delivery of A BET Protein Degrader via A CEACAM6-Targeted ADC – Highlighting Preclinical Efficacy Against Pancreatic Cancer
Synopsis
- Exploring the properties of BET protein degrader as a payload and inducing the bystander effect
- Examining the pharmacological profile of our CEACAM6-EBET ADC
- Reviewing data portraying cancer-cell-killing activity and stromal modulation activity in PDX models
3:00 pm Targeted Protein Degraders as Next Generation Antibody Payloads
3:30 pm Afternoon Break & Scientific Poster Session
Synopsis
This is an informal session to help you connect with your peers in a relaxed atmosphere and forge new, beneficial relationships. With an audience of bioconjugate experts looking to stay on top of this evolving space, this is your chance to present, review and discuss posters featuring cutting-edge work from drug discovery right through to exciting clinical trial updates.
Advancing the Future of Nucleotide Based Therapeutics With Antibody-Oligonucleotide Conjugates for Revolutionizing Targeted Delivery
4:15 pm Session Reserved for Goodwin Biotechnology
4:30 pm FORCE™ Platform Enables TFR1-Mediated Delivery of Therapeutics for Serious Muscle Diseases
Synopsis
- Discovering key elements of the platform and considerations for oligonucleotide conjugate selection
- Understanding the FORCE translation into the clinic and the ACHIEVE & DELIVER trial data in DM1 and DMD
- Reviewing the FORCE efficacy in preclinical models of FSHD
5:00 pm Endosomal Escape Vehicle (EEV)-Conjugated Phosphorodiamidate Morpholino Oligomer (PMO) Therapeutics for the Treatment of Duchenne Muscular Dystrophy
Synopsis
- Understanding endosomal escape vehicle platform – an enhance lipid nanoparticlemediated delivery of genomic medicines
- Considering the value proposition of using endosomal escape vehicle-oligonucleotides for Duchenne
- Analyzing preclinical data to support this novel approach
5:30 pm Pioneering Targeting Ligands to Create Groundbreaking Conjugates
Synopsis
- Pioneering targeting ligands to create groundbreaking conjugates
- Harnessing siRNA for cancer treatment with the potential to revolutionize cancer therapies
- Insights into the next frontier of targeted cancer interventions